Galectin-3与宫颈组织癌变关系的Meta分析  

Meta-analysis of the relationship between Galectin-3 and cervical tissue canceration.

作　　者：沐超 胡新荣 MU Chao;HU Xin-rong(Cancer Institute of Guangdong Medical University,Dongguan 523000,Guangdong,CHINA)

机构地区：[1]广东医科大学肿瘤研究所,广东东莞523000

出　　处：《海南医学》2021年第3期377-381,共5页Hainan Medical Journal

摘　　要：目的系统评价半乳糖凝集素-3(Galectin-3)与宫颈组织癌变的关系。方法通过“Galectin-3、宫颈上皮内瘤变、宫颈癌”等关键词检索CBMdisc、CNKI、万方、维普、Pubmed、Web of science、Medline七个数据库,检索时间自建库至2020年7月。然后,两位研究人员按照纳入和排除标准独立进行文献的筛选,并提取资料。在对各个研究进行质量评价后,使用Stata12.0软件对纳入的研究进行分析。结果纳入17篇文献,共2262例受试者,包括正常宫颈组织293例、CIN 802例、宫颈癌1167例。Galectin-3表达阳性率的OR值(95%CI)为:宫颈癌组和正常宫颈组13.54(9.14,20.06)、宫颈癌组与CIN组3.86(2.65,5.61)、CIN组和正常宫颈组3.06(1.50,6.22)。结论Galectin-3表达上调会促进正常宫颈组织向宫颈癌的发展,检测Galectin-3的表达有助于评估宫颈癌的预后评估。Objective To systematically evaluate the relationship between Galectin-3 and cervical tissue canceration.Methods Seven databases including CBMdisc,CNKI,WanFang,VIP,Pubmed,Web of Science,and Medline were searched by keyword"Galectin-3,Cervical Intraepithelial Neoplasia,Cervical Cancer",and the retrieval time was from building database to July,2020.Two researchers then independently screened the literature according to inclusion and exclusion criteria and extracted the data.After evaluating the quality of each study,the included studies were analyzed by using Stata12.0 software.Results Seventeen literatures were included,involving a total of 2262 subjects,including 293 cases of normal cervical tissue,802 cases of CIN,and 1167 cases of cervical cancer.The OR(95%CI)of the positive rate of Galectin-3 expression was 13.54(9.14,20.06)for the cervical cancer group,and the normal cervical group,3.86(2.65,5.61)for the cervical cancer group and CIN group,3.06(1.50,6.22)for the CIN group and the normal cervical group.Conclusion The up-regulated expression of Galectin-3 will promote the development of normal cervical to cervical cancer,and detection of Galectin-3 expression is helpful to evaluate the prognosis of cervical cancer.

关 键 词：半乳糖凝集素-3 β半乳糖苷酶类 宫颈上皮内瘤变 宫颈癌 生物标记 预后 META分析 

分 类 号：R737.33[医药卫生—肿瘤]